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Summary
Dengue and Zika viruses are closely related mosquitoborne flaviviruses with similar transmission cycles, distribution throughout the 
tropics and subtropics, and disease manifestations including fever, rash, myalgia, and arthralgia. For patients with suspected dengue 
or Zika virus disease, nucleic acid amplification tests (NAATs) are the preferred method of diagnosis. Immunoglobulin M (IgM) 
antibody testing can identify additional infections and remains an important tool for the diagnosis of these diseases, but interpreting 
the results is complicated by cross-reactivity, and determining the specific timing of infection can be difficult. These limitations are 
a particular challenge for pregnant women in determining whether Zika virus infection occurred during or before the pregnancy.
This report summarizes existing and new guidance on dengue and Zika virus diagnostic testing for patients with a clinically 
compatible illness who live in or recently traveled to an area where there is risk for infection with both viruses. CDC recommendations 
for screening of asymptomatic pregnant women with possible Zika virus exposure are unchanged. For symptomatic nonpregnant 
persons, dengue and Zika virus NAATs should be performed on serum collected ≤7 days after symptom onset. Dengue and Zika 
virus IgM antibody testing should be performed on NAAT-negative serum specimens or serum collected >7 days after onset of 
symptoms. For symptomatic pregnant women, serum and urine specimens should be collected as soon as possible within 12 weeks 
of symptom onset for concurrent dengue and Zika virus NAATs and IgM antibody testing. Positive IgM antibody test results 
with negative NAAT results should be confirmed by neutralizing antibody tests when clinically or epidemiologically indicated, 
including for all pregnant women. Data on the epidemiology of viruses known to be circulating at the location of exposure and 
clinical findings should be considered when deciding which tests to perform and for interpreting results.
Patients with clinically suspected dengue should receive appropriate management to monitor and treat shock and hemorrhage. 
Women with laboratory evidence of possible Zika virus infection during pregnancy and their infants should be evaluated and 
managed for possible adverse outcomes. Dengue and Zika virus disease are nationally notifiable conditions, and cases should be 
reported to public health authorities.
Corresponding author: Tyler M. Sharp, Division of Vector-Borne 
Diseases, National Center for Emerging and Zoonotic Infectious 
Diseases, CDC. Telephone: 787-706-2245; Email: tsharp@cdc.gov.
Introduction
Dengue and Zika viruses are closely related mosquitoborne 
flaviviruses with similar transmission cycles, distribution 
throughout the tropics, and disease manifestations (1,2). 
Although the four dengue viruses are the predominant 
flaviviruses transmitted by Aedes mosquitoes in the tropics and 
subtropics, the recent emergence of Zika virus has complicated 
diagnostic testing considerations and interpretation. For 
patients with suspected dengue or Zika virus disease, 
nucleic acid amplification tests (NAATs) are the preferred 
method of diagnosis because they can provide confirmed 
evidence of infection and distinguish the specific virus (3,4). 
Immunoglobulin M (IgM) and neutralizing antibody testing 
also can be used to identify dengue and Zika virus infections, 
particularly in patients who present after viral nucleic acid 
is no longer detectable (4–7). However, dengue and Zika 
virus antibody testing is complicated by cross-reactivity that 
might preclude conclusive determination of which flavivirus 
is responsible for the person’s recent infection (8). Moreover, 
because flavivirus IgM antibodies are often detectable for 
months after an infection, determining the specific timing of 
infection can be difficult, especially among persons who live 
in or frequently travel to areas with risk for dengue or Zika 
virus infection (5,9–11). These limitations are a particular 
challenge for pregnant women in determining whether Zika 
virus infection occurred during or before the pregnancy.
Previous guidance provided diagnostic testing recommendations 
for pregnant and nonpregnant persons with possible Zika 
virus infection (12–14). Existing CDC recommendations for 
screening of asymptomatic pregnant women with possible Zika 
virus exposure are unchanged (12). This report updates CDC’s 
diagnostic testing guidance for patients, including pregnant 
women, with an illness clinically compatible with dengue or 
Zika virus disease and who reside in or recently traveled to an 
area where there is risk for infection with both dengue and 
Zika viruses.
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Purpose
These guidelines provide federal, state, territorial, and local 
health departments with recommended diagnostic algorithms 
and interpretation of test results for evaluation of dengue and 
Zika virus infection in patients with a clinically compatible illness 
and relevant epidemiologic exposure. These recommendations 
have incorporated lessons learned and feedback from public 
health and commercial laboratories regarding previously 
published guidelines (12,13,15,16). Because recommendations 
are intended for health departments, laboratories and health 
departments can adapt the recommendations according to local 
needs, resource availability, capacity for diagnostic testing, and 
epidemiologic conditions. Up-to-date information on areas 
where there is risk for dengue and Zika virus infection and 
ongoing outbreaks are available online (17,18).
Methods
A work group comprising CDC epidemiologists, physicians, 
and laboratorians was convened in January 2018. The group 
reviewed data regarding the natural history of dengue and 
Zika virus infections and the resulting immune response. 
In addition, they evaluated evidence on the performance of 
diagnostic tests to detect and differentiate dengue and Zika 
virus infections. Primary data sources included published 
peer-reviewed studies identified through searches of PubMed 
(n = 97) and Medline (n = 276) and references cited in relevant 
articles (n = 4). Unpublished data also were considered, 
including package inserts for products submitted to the U.S. 
Food and Drug Administration (FDA) for approval (n = 4) 
or Emergency Use Authorization (n = 19), and data derived 
from diagnostic testing performed at CDC (19). Evidence 
evaluated included the sensitivity and specificity of NAAT and 
IgM antibody assays by day postonset of illness, concordance of 
NAAT and serologic test results, and frequency of confirmation 
of IgM antibody detection with virus-specific neutralizing 
antibodies. Testing recommendations might be updated when 
additional assays have been evaluated and are approved for 
routine use by FDA.
Dengue and Zika Virus Epidemiology 
and Clinical Manifestations
Dengue and Zika viruses are transmitted by Aedes species 
mosquitoes, primarily Aedes aegypti, which are present 
throughout the tropics and subtropics (1,2). Infection with 
any of these viruses can result in an acute illness that includes 
fever, rash, myalgia, and arthralgia. Certain patients with 
dengue will progress to potentially fatal severe dengue, for 
which appropriate clinical management can reduce the case-
fatality rate among hospitalized patients to <0.5% (20,21). The 
incidence of dengue has doubled each decade since 1990 such 
that, in 2013, an estimated 58 million symptomatic infections 
and 13,000 deaths occurred worldwide (2,22,23).
Zika virus was first isolated in Uganda in 1947. For the 
next 60 years, only sporadic cases were identified in Africa 
and Asia until 2007, when the first outbreak was recognized 
in Micronesia (24–27). During 2013–2015, approximately 
30,000 suspected Zika virus disease cases were reported from 
French Polynesia and other Pacific islands. During 2015–2016, 
large outbreaks occurred throughout much of the Americas 
(1,28,29). During these recent outbreaks, new modes of 
transmission (e.g., congenital, perinatal, and sexual) and 
clinical manifestations (e.g., fetal loss, microcephaly, serious 
birth defects of the brain and eye, Guillain-Barre syndrome, 
other neurologic syndromes, and severe thrombocytopenia) 
(1,29,30) were identified.
Dengue and Zika Virus Infections and 
Immune Response
Most dengue and Zika virus infections are asymptomatic 
(2,27,31). Among symptomatic persons, the incubation 
period from infection until disease onset is a few days to 
2 weeks (32–34). Dengue and Zika virus RNA are likely to 
be detected in serum from approximately 2 days before to 
1 week after illness onset (4,5,35,36). However, detection of 
Zika virus nucleic acid might be prolonged in some patients, 
especially pregnant women (5,37–41). Zika virus RNA also 
can be detected in other body fluids (e.g., whole blood, urine, 
saliva, amniotic fluid, semen, and breast milk), and some 
reports suggest that viral RNA might be found at higher levels 
or for longer duration in some of these specimens (7,42–48). 
Dengue virus nonstructural protein-1 (NS1) antigen also can 
be detected in serum with similar frequency and duration as 
dengue viral RNA (35).
IgM antibodies directed against dengue and Zika virus 
typically develop during the first week of illness (4,5,7); 
however, limited published data exist on the duration of IgM 
antibodies following dengue or Zika virus infection. Among 
adults with dengue virus infection in Taiwan, 71% (31 of 44) 
had IgM antibodies against the envelope protein detectable 
at 6 months after acute infection, and 46% (20 of 44) had 
detectable IgM at 12 months after onset (49). Among 266 
patients from Brazil with confirmed dengue virus infection, 
>70% had IgM antibody against the NS1 protein detected for 
>90 days after illness onset (49,50). In one study of patients 
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with symptomatic Zika virus infection, 87% (52 of 60) had 
detectable IgM antibodies >60 days after symptom onset (5). 
In another cohort study of persons with confirmed Zika virus 
infection, 73% (45 of 62) had detectable IgM antibodies at 
12–19 months after acute illness (51). Data for closely related 
flaviviruses (i.e., West Nile and yellow fever viruses) indicate 
that IgM antibodies might be detectable in serum for months 
or years after initial infection (9–11).
Neutralizing antibodies develop shortly after IgM antibodies 
and consist primarily of IgG antibodies. Neutralizing antibodies 
persist for multiple years after flavivirus infections and usually 
confer long-lived immunity (52–54). In persons previously 
infected with or vaccinated against a flavivirus, subsequent 
infection with another flavivirus (i.e., secondary flavivirus 
infection) can result in both a diminished IgM response and 
a rapid increase in neutralizing antibodies against multiple 
flaviviruses, which might preclude conclusive determination 
of which virus was responsible for the person’s recent infection 
(4,50,55–59).
Dengue and Zika Virus 
Diagnostic Testing
Dengue and Zika virus diagnostic testing employs both 
molecular and serologic methods; testing for dengue virus also 
includes detection of NS1 antigen. For patients with suspected 
dengue or Zika virus disease, molecular testing can provide 
confirmed evidence of infection, and NAATs can distinguish 
the specific virus. However, despite the high sensitivity and 
specificity of NAAT, both false-negative and false-positive 
results can occur (3,60–64).
With IgM antibody testing, false-positive results are 
more common than with NAAT and can occur because of 
nonspecific reactivity or cross-reactivity with other flaviviruses 
(e.g., West Nile, St. Louis encephalitis, Japanese encephalitis, 
or yellow fever viruses) (4,6,8). In addition, because IgM 
antibodies might be detectable for months or longer after 
infection, determining the specific timing of dengue and Zika 
virus infection can be difficult, especially among persons who 
live in or frequently travel to areas where the disease is endemic. 
These limitations of serologic testing are a particular challenge 
for pregnant women and attempts to determine whether 
Zika virus infection might have occurred during or before 
pregnancy. With decreased incidence and thus lower likelihood 
of Zika virus infection, a higher proportion of positive IgM 
antibody tests will be due to cross-reactivity with dengue or 
other flavivirus antibodies, a previous Zika virus infection, or 
false-positive results.
Plaque reduction neutralization tests (PRNTs) are 
quantitative assays that measure virus-specific neutralizing 
antibody titers for dengue, Zika, and other flaviviruses to which 
the patient might have been exposed (56,65). For diagnostic 
testing, CDC uses a PRNT with a 90% cutoff value titer ≥10 
in serum and ≥2 in cerebrospinal fluid (the typical starting 
dilutions) to define positive specimens. PRNTs can resolve 
false-positive IgM antibody results caused by nonspecific 
reactivity and, in certain cases, can help identify the infecting 
virus. In primary flavivirus infections, a neutralizing antibody 
titer ≥4-fold higher than titers against other flaviviruses to 
which the person might have been exposed usually determines 
the specific infecting flavivirus. Recent findings indicate that 
neutralizing antibody titers might be able to differentiate 
dengue and Zika virus infections, particularly in specimens 
collected ≥3 months after illness onset (66). However, at 
12–19 months after confirmed Zika virus infection, 17 (27%) 
of 62 persons in Florida still had neutralizing antibody titers 
that could not distinguish between dengue and Zika viruses 
(51). On the basis of previous flavivirus research and limited 
data specific to dengue and Zika viruses, the historic use of 
a four-fold higher titer by PRNT might not discriminate 
between dengue and Zika virus antibodies during the acute 
illness, especially following secondary flavivirus infections 
(8,56,57,66). Consequently, in areas with high prevalence of 
dengue and Zika virus infections, PRNT might not define 
the infecting virus for a significant proportion of cases (8). 
Therefore, such jurisdictions should make informed decisions 
about the utility of PRNT depending on the prevalence of 
dengue and Zika virus infection and observed performance 
of PRNT to confirm IgM test results.
Most state health departments and numerous commercial 
laboratories perform dengue and Zika virus diagnostic testing, 
and confirmatory testing is available through multiple state 
health departments and CDC. FDA has cleared three assays 
for the diagnosis of dengue: 1) a NAAT for use on serum and 
whole blood, 2) an enzyme immunoassay that detects dengue 
virus NS1 antigen in serum, and 3) an enzyme immunoassay 
that detects dengue virus IgM antibodies in serum (63,66,67). 
FDA has cleared one enzyme immunoassay to detect Zika 
virus IgM antibodies in serum (68). FDA also has issued 
Emergency Use Authorizations for multiple NAAT and other 
IgM antibody assays to diagnose Zika virus infection (19). 
Various Zika virus NAATs can be used on serum, plasma, whole 
blood, cerebrospinal fluid, urine, or amniotic fluid. Zika virus 
IgM antibody assays can be used variably on serum, plasma, 
whole blood, or cerebrospinal fluid. Efforts are ongoing to 
develop and validate serologic assays to reliably differentiate 
dengue and Zika virus infections and to distinguish recent and 
previous infections (69).
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During a dengue outbreak, jurisdictions might elect to forego 
Zika virus testing in nonpregnant persons with suspected 
dengue. Similarly, during a Zika virus outbreak, jurisdictions 
might elect to forego dengue virus testing in nonpregnant 
persons with suspected Zika virus disease. In both scenarios, 
because of possible adverse outcomes, pregnant women should 
be tested by NAAT for evidence of infection with both dengue 
and Zika viruses and by serology for evidence of infection with 
the virus causing the outbreak. Patients for whom testing is 
unable to determine the infecting flavivirus should be clinically 
managed for possible dengue and, in pregnant patients, Zika 
virus infection because they might have been infected with 
either virus.
Clinical and Epidemiologic 
Criteria for Testing
Dengue and Zika virus testing should be considered in a 
patient with a clinically compatible illness who lives in or 
recently traveled to an area where there is risk for infection 
with these viruses. Zika virus testing also should be considered 
in symptomatic patients who had sex with someone who lives 
in or recently traveled to those areas (17,18).
The U.S. surveillance case definitions for dengue and Zika 
virus disease include both clinical and diagnostic testing 
criteria. The case definition for dengue includes fever with one 
or more other characteristic finding (i.e., nausea, vomiting, 
rash, headache, retro-orbital pain, myalgia, arthralgia, positive 
tourniquet test, leukopenia, or a dengue warning sign) (70). 
For Zika virus disease, the surveillance case definition requires 
a clinically compatible illness with fever, rash, arthralgia, or 
conjunctivitis (71). For patients who live in or recently traveled 
to areas where there is risk for dengue and Zika virus infection, 
the broader clinical findings (i.e., fever, rash, arthralgia, or 
conjunctivitis) should be taken into account when considering 
testing for possible infection with either virus. Other infectious 
etiologies to consider in the differential diagnosis include 
chikungunya, malaria, rubella, measles, hepatitis A, parvovirus, 
adenovirus, enterovirus, leptospirosis, rickettsiosis, and group A 
streptococcal infections.
Pregnant women face potential complications from infection 
with either dengue or Zika virus (72). Dengue virus infection 
might increase the risk for maternal death or obstetric 
complications (e.g., hemorrhage, preeclampsia, eclampsia, and 
vertical transmission) during the peripartum period (73–75). 
Zika virus infection during pregnancy can result in fetal loss, 
microcephaly, or serious birth defects including structural 
abnormalities of the brain and eye (30,72).
Recommended Testing for 
Symptomatic Nonpregnant Patients
For nonpregnant persons with a clinically compatible 
illness, dengue and Zika virus NAATs should be performed 
on serum collected ≤7 days after symptom onset (Figure 1). 
Various NAATs also can be performed on plasma, whole blood, 
cerebrospinal fluid, or urine. For symptomatic persons with 
possible exposure to dengue and Zika virus, a positive NAAT 
result typically provides evidence of acute infection, and no 
antibody testing is indicated (Table). However, patients for 
whom the diagnosis has epidemiologic or clinical significance 
(e.g., first local transmission in area, new transmission mode, 
patient has an unusual clinical syndrome, or diagnosis will 
affect clinical management), a repeat NAAT should be 
performed on newly extracted RNA from the same specimen 
to rule out false-positive test results.
Because of the decline in the level of viremia over time and 
possible inaccurate reporting of dates of illness onset, a negative 
NAAT result does not exclude dengue or Zika virus infection. 
Therefore, dengue and Zika virus IgM antibody testing should 
be performed on NAAT-negative serum specimens and serum 
collected >7 days after onset of symptoms. Certain IgM 
antibody assays also can be used on plasma, whole blood, or 
cerebrospinal fluid. Some laboratories might choose to perform 
dengue and Zika virus NAATs and IgM antibody testing 
simultaneously rather than sequentially.
For serum specimens collected <7 days after onset of 
symptoms, the combination of a negative NAAT result and 
negative IgM antibody testing suggests the patient did not 
have a recent flavivirus infection. However, in the absence 
of NAAT testing, a negative acute IgM antibody test might 
reflect specimen collection before development of detectable 
antibodies and does not rule out infection. For specimens 
collected from 7 days to 12 weeks after onset of symptoms, a 
negative IgM antibody result to both dengue and Zika virus 
rules out recent infection with either virus, and testing for 
other etiologies should be considered.
If either dengue or Zika virus IgM antibody testing is 
positive without a positive NAAT or NS1 antigen test, and 
definitive diagnosis is needed for clinical or epidemiologic 
purposes, confirmatory PRNTs should be performed against 
dengue, Zika, and other flaviviruses endemic to the region 
where exposure occurred. For indeterminate IgM antibody 
results, IgM antibody testing should be repeated on the same 
specimen or PRNTs performed. In the setting of positive IgM 
antibody testing, a PRNT titer ≥10 against dengue virus with 
negative PRNTs (i.e., <10) against Zika and other flaviviruses 
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FIGURE 1. Dengue and Zika virus testing recommendations for nonpregnant persons with a clinically compatible illness and risk for infection 
with both viruses*
Specimen collected ≤7 days
postsymptom onset
Perform dengue and
Zika virus NAATs
Negative dengue and 
Zika virus NAATs
Specimen collected >7 days
postsymptom onset
Acute
dengue virus infection
Perform dengue and
Zika virus PRNTs
Perform dengue and
Zika virus IgM serology
No evidence of dengue or
Zika virus infection 
Positive dengue or
Zika virus IgM
Negative dengue and
Zika virus IgM
Positive
dengue virus NAAT
Positive
Zika virus NAAT
Dengue virus PRNT ≥10
and
Zika virus PRNT <10
Dengue virus PRNT <10
and
Zika virus PRNT ≥10
Dengue virus PRNT ≥10
and
Zika virus PRNT ≥10
Dengue virus PRNT <10
and
Zika virus PRNT <10
Acute
Zika virus infection
Recent
dengue virus infection
Recent
Zika virus infection
Recent
avivirus infection
Abbreviations: IgM = immunoglobulin M; NAAT = nucleic acid amplification test; PRNT = plaque reduction neutralization test.
* Specimen and test selection: Dengue and Zika virus NAATs, IgM antibody testing, and PRNTs should be performed on serum. Some NAATs also can be performed on 
plasma, whole blood, cerebrospinal fluid, or urine, and some antibody tests can be performed on plasma, whole blood, or cerebrospinal fluid. Laboratories might 
choose to perform dengue and Zika virus NAATs and IgM antibody testing simultaneously rather than sequentially, or to perform dengue virus nonstructural 
protein-1 testing instead of dengue virus NAAT.
 Indications to repeat assay(s): If the patient’s illness has epidemiologic or clinical significance (e.g., first case of local transmission in area, new transmission mode, or 
unusual clinical syndrome), repeat a positive NAAT on newly extracted RNA from the same specimen. For indeterminate IgM antibody test results, repeat IgM 
antibody testing or perform PRNT on the same specimen. In areas where PRNTs are not performed, report the indeterminate results and request a second serum 
specimen for IgM antibody testing.
 Interpretation of results: Dengue and Zika virus IgM antibodies can be detected in serum for months following infection. The specific timing of infection cannot be 
determined. Data on the epidemiology of viruses known to be circulating at the location of exposure and clinical findings should be considered when interpreting 
the results of serologic diagnostic testing. 
is considered evidence of recent dengue virus infection (Table). 
Conversely, a PRNT titer ≥10 against Zika virus with negative 
PRNTs against dengue and other flaviviruses is evidence of 
recent Zika virus infection. A PRNT titer ≥10 for both Zika 
and dengue virus (or another flavivirus) provides evidence of a 
recent infection with a flavivirus but precludes identification of 
the specific infecting virus or timing of infection on the basis 
of laboratory testing alone.
Negative PRNT titers against dengue and Zika virus in a 
serum specimen collected >7 days after illness onset rule out 
infection with either virus (Table). Without confirmatory 
PRNTs, determining whether positive IgM antibody results 
reflect a recent flavivirus infection or a false-positive result is 
not possible. In areas where PRNTs are not performed,  positive 
dengue and negative Zika virus IgM antibody tests should be 
interpreted as a “presumptive recent dengue virus infection,” 
positive Zika and negative dengue virus IgM antibody tests 
should be interpreted as a “presumptive recent Zika virus 
infection,” and positive dengue and Zika virus IgM antibody 
tests should be interpreted as a “presumptive recent flavivirus 
infection.” If only one IgM antibody test was performed and 
was positive and PRNT was not performed, the second IgM 
test should be performed. If it is not possible to perform the 
second test, results of the first test should be interpreted as a 
“presumptive recent flavivirus infection.”
For nonpregnant patients who live in or recently returned 
from an area where there is an ongoing outbreak in which only 
one virus has been detected to be circulating, jurisdictions 
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TABLE. Interpretation of dengue and Zika virus diagnostic test results for patients with a clinically compatible illness and risk for infection with 
both viruses
Dengue and Zika virus NAATs Interpretation
Positive dengue virus assay, negative Zika virus assay Acute dengue virus infection
Positive Zika virus assay, negative dengue virus assay Acute Zika virus infection
Positive (both assays) Acute dengue and Zika virus co-infection
Negative (both assays) No evidence of dengue or Zika virus infection*
Dengue and Zika virus IgM 
antibodies
Dengue virus 
PRNT
Zika virus 
PRNT Nonpregnant patients Pregnant women
Positive (either assay)†,§ ≥10 <10 Recent dengue virus infection Dengue virus infection, 
timing cannot be determined
Positive (either assay)†,§ <10 ≥10 Recent Zika virus infection Zika virus infection,  
timing cannot be determined
Positive (either assay)† ≥10 ≥10 Recent flavivirus infection¶ Flavivirus infection, 
timing cannot be determined
Any result <10 <10 No evidence of dengue or 
Zika virus infection**
No evidence of dengue or 
Zika virus infection**
Positive dengue virus assay, 
negative Zika virus assay
Not performed Presumptive recent 
dengue virus infection
Presumptive dengue virus infection, 
timing cannot be determined
Positive Zika virus assay, negative 
dengue virus assay
Not performed Presumptive recent 
Zika virus infection
Presumptive Zika virus infection, 
timing cannot be determined
Positive (both assays) Not performed Presumptive recent 
flavivirus infection¶
Presumptive flavivirus infection, 
timing cannot be determined
Positive dengue virus assay, Zika 
virus assay not performed
Not performed Presumptive recent 
flavivirus infection¶
Presumptive flavivirus infection, 
timing cannot be determined
Positive Zika virus assay, dengue 
virus assay not performed
Not performed Presumptive recent 
flavivirus infection¶
Presumptive flavivirus infection, 
timing cannot be determined
Negative (both assays) Not performed No evidence of dengue or 
Zika virus infection**
No evidence of dengue or 
Zika virus infection**
Negative dengue virus assay, Zika 
virus assay not performed
Not performed No evidence of 
dengue virus infection**
No evidence of 
dengue virus infection**
Negative Zika virus assay, dengue 
virus assay not performed
Not performed No evidence of 
Zika virus infection**
No evidence of 
Zika virus infection**
Abbreviations: IgM = immunoglobulin M; NAATs = nucleic acid amplification tests; PRNT = plaque reduction neutralization test.
 * In the absence of testing to detect IgM antibodies, negative NAAT results might reflect collection after clearance of detectable viral RNA and does not rule out infection.
 † Includes presumptive positive, indeterminate, and equivocal IgM antibody results that are not resolved by retesting.
 § IgM and PRNT antibody testing infrequently provide discordant results (e.g., dengue virus IgM positive, Zika virus IgM negative with dengue virus PRNT titer <10, 
Zika virus PRNT titer ≥10; or dengue virus IgM negative, Zika virus IgM positive with dengue virus PRNT titer ≥10, Zika virus PRNT titer <10). In such cases, report 
results as “presumptive flavivirus infection” and request a second specimen for retesting.
 ¶ The patient should be clinically managed for possible dengue and Zika virus infection because they might have been infected with either or both viruses. Data on 
the epidemiology of viruses known to be circulating at the location of exposure and clinical findings should be considered when interpreting the results.
 ** In the absence of NAAT, negative IgM or neutralizing antibody testing in specimens collected ≤7 days after illness onset might reflect collection before the 
development of a detectable antibody response and does not rule out infection.
might reasonably elect to only perform testing for the virus 
causing the outbreak and not confirm IgM results by PRNT. If 
the patient does not reside in and has not recently traveled to 
an area with circulation of both viruses, and the only potential 
epidemiologic exposure is sexual contact with a person who 
has recently traveled to those areas, then the patient should 
only be tested for Zika virus infection.
Recommended Testing for 
Symptomatic Pregnant Women
Pregnant women with a clinically compatible illness and 
recent possible exposure to dengue and Zika virus should 
have concurrent diagnostic testing for dengue and Zika virus 
infection performed by NAAT and IgM antibody testing 
on a serum specimen and NAAT on a urine specimen to 
diagnose Zika virus infection (Figure 2). Specimens should 
be collected as soon as possible for dengue and Zika virus 
NAATs and within 12 weeks of symptom onset for Zika 
virus NAAT. Various NAATs also can be performed on 
plasma, whole blood, cerebrospinal fluid, or amniotic fluid; 
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FIGURE 2. Dengue and Zika virus testing recommendations for pregnant persons with a clinically compatible illness and risk for infection with 
both viruses*
Specimen collected ≤12 weeks 
postsymptom onset 
Perform dengue and Zika virus NAATs and 
dengue and Zika virus IgM serology
Acute
dengue virus infection
Perform dengue and
Zika virus PRNTs
No evidence of dengue
or Zika virus infection
Negative dengue and Zika virus NAATs and
positive dengue or Zika virus IgM 
Negative dengue and Zika virus NAATs and
negative dengue or Zika virus IgM 
Positive
dengue virus NAAT
Positive
Zika virus NAAT
Acute
Zika virus infection
Dengue
virus infection
Zika
virus infection
Flavivirus
infection
Dengue virus PRNT <10
and
Zika virus PRNT <10 
Dengue virus PRNT ≥10
and
Zika virus PRNT ≥10
Dengue virus PRNT <10
and
Zika virus PRNT ≥10 
Dengue virus PRNT ≥10
and
Zika virus PRNT <10 
Abbreviations: IgM = immunoglobulin M; NAAT = nucleic acid amplification test; PRNT = plaque reduction neutralization test.
* Specimen and test selection: Dengue and Zika virus NAATs, IgM antibody testing, and PRNTs should be performed on serum. Some NAATs also can be performed on 
plasma, whole blood, cerebrospinal fluid, or urine, and some antibody tests can be performed on plasma, whole blood, or cerebrospinal fluid. Dengue virus NAAT 
does not need to be performed on specimens collected >7 days after illness onset. Some laboratories might choose to perform dengue virus nonstructural protein-1 
testing instead of dengue virus NAAT. 
 Indications to repeat assay(s): If Zika virus NAAT is positive on a single specimen but IgM antibody tests are negative, repeat NAAT on newly extracted RNA from the 
same specimen. For indeterminate IgM antibody test results, repeat IgM antibody testing or perform PRNT on the same specimen. In areas where PRNTs are not 
performed, report the indeterminate results and request a second serum specimen for IgM antibody testing. 
 Interpretation of results: Dengue and Zika virus IgM antibodies can be detected in serum for months following infection. The specific timing of infection cannot be 
determined. Data on the epidemiology of viruses known to be circulating at the location of exposure and clinical findings should be considered when interpreting 
the results of serologic diagnostic testing. 
IgM antibody testing can be performed on plasma, whole 
blood, or cerebrospinal fluid. A positive NAAT result on 
any specimen typically provides evidence of recent infection. 
However, if NAAT is only positive for Zika virus on a single 
specimen and IgM antibody testing is negative, the NAAT 
should be repeated on newly extracted RNA from the same 
specimen to rule out false-positive test results.
If both dengue and Zika virus NAATs are negative but either 
IgM antibody test is positive, confirmatory PRNTs should be 
performed against dengue, Zika, and other flaviviruses endemic 
to the region where exposure occurred. For indeterminate IgM 
antibody results, IgM antibody testing should be repeated on 
the same specimen or PRNTs performed. If IgM antibody 
results are positive for one virus but the assay for the other 
virus was not performed, the second assay should be performed 
to appropriately interpret results. If the second assay is not 
performed, the single positive result should be interpreted 
as “presumptive flavivirus infection.” The interpretation for 
IgM and neutralizing antibody test results in a symptomatic 
pregnant woman is similar to that for nonpregnant patients; 
however, because dengue and Zika virus IgM antibodies can 
be detected in serum for months after an infection, the specific 
timing of infection cannot be determined, and other factors 
(e.g., epidemiologic and clinical findings) should be used to 
assess the likelihood that the current illness was due to either 
dengue or Zika virus and that exposure occurred during the 
pregnancy (Table). Pregnant women living in or returning from 
an area where there is an ongoing outbreak in which only one 
virus has been detected to be circulating should be tested by 
NAAT for evidence of infection with both dengue and Zika 
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viruses; however, jurisdictions might elect to perform serologic 
diagnostic testing solely for the virus causing the outbreak.
Zika virus testing recommendations for asymptomatic 
pregnant women are unchanged (12). For asymptomatic 
pregnant women without ongoing risk for possible Zika virus 
infection, testing for Zika virus infection is not routinely 
recommended. However, testing should be considered using a 
shared decision-making model, in which patients and providers 
work together to make decisions about testing and care plans on 
the basis of patient preferences and values, clinical judgment, 
a balanced assessment of risks and expected outcomes, and the 
jurisdiction’s recommendations.
Management of Patients with 
Dengue or Zika Virus Infection
Data on the epidemiology of viruses known to be 
circulating at the location of exposure and clinical findings 
should be considered in clinical and testing decisions and 
when interpreting results (17,18). All patients with clinically 
suspected dengue should receive appropriate management 
to monitor for shock and reduce the risk for complications 
resulting from plasma leakage and organ damage without 
waiting for diagnostic test results to be received (20). Women 
with laboratory evidence of possible Zika virus infection 
during pregnancy and their infants should be evaluated and 
managed for possible adverse outcomes, including congenital 
Zika virus infection (12,76). Patients for whom testing is 
unable to determine the most recent infecting flavivirus should 
be clinically managed for possible dengue and, in pregnant 
patients, Zika virus infection because they might have been 
infected with either virus. Health care providers with questions 
about test result interpretation should consult with state or 
local public health authorities for assistance.
Reporting Dengue and Zika Virus 
Disease Cases
Dengue and Zika virus disease are nationally notifiable 
conditions. Health care providers are encouraged to report 
suspected dengue and Zika virus disease cases to their state, 
territorial, or local health departments to facilitate diagnosis and 
mitigate the risk for local transmission. State and territorial health 
departments should report cases to CDC according to the Council 
of State and Territorial Epidemiologists case definitions (70,71).
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